Unknown

Dataset Information

Is there a shift from cardiovascular to cancer death in lipid-lowering trials? A systematic review and meta-analysis.


ABSTRACT:

Background

Lipid-lowering therapy (LLT) reduces cardiovascular (CV) events, but data are conflicting on all-cause mortality, especially among older adults. Though LLT does not induce cancer, some randomized clinical trials (RCTs) found a pattern of increased cancer death under LLT. Our objective was to assess a possible shift from CV to cancer death in LLT trials (i.e. an increase in cancer and decrease in CV death) and to investigate potential subgroups at risk.

Methods

We performed a systematic review and meta-analysis. We retrieved RCTs from MEDLINE, Embase, and Cochrane Central until 08/2023. We extracted the number of CV and cancer deaths in the treatment vs. in the control arm, calculated the relative risk (RR) by dividing the risk of death in the treatment over the ri

SUBMITTER: Bolt L 

PROVIDER: S-EPMC10852259 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature